Company Overview and News

4
Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy

2018-10-08 zacks
In this episode of ETF Spotlight, I talked with Brad Loncar, CEO of Loncar Investments. Brad created the Loncar Cancer Immunotherapy index and the China BioPharma index.
FCN BLUE FATE MRTX CHBO FPRX CNCR BLUE

143
Major Biopharma Catalysts to Watch For in October

2018-10-06 247wallst - 7
Biotech and pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to great, should a study come back negative or a candidate not be approved. Some companies can see massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U.
TCDA NTGN MRK TGTX AVEO MRTX TRVN MRUS RGNX

2
MRTX / Mirati Therapeutics, Inc. FORM S-3ASR

2018-09-06 sec.gov
Form S-3ASR Table of Contents As filed with the Securities and Exchange Commission on September 6, 2018 Registration No. 333-
MRTX

152
Small Caps Are Rising, Biotechs Can't Be Far Behind

2018-09-05 seekingalpha - 10
While much attention is being riveted on the S&P 500's new all-time high eclipsing the January one, small caps accomplished that in May.
VRTX ECYT VSTM TRXC VKTX ENL CVS LGNDZ RGNX IMMU BIIB LGNYZ REGI HRTX NVTA NBIX ARWR SRPT ICPT VKTXW XLRN FNKO MRTX LGNZZ LGND NVS HEAR LGNXZ NTRA UNH PFE ENDP

6
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

2018-08-24 zacks
Launched on 07/19/2012, the Invesco DWA SmallCap Momentum ETF (DWAS - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Blend segment of the US equity market.
AVX CDNA PLUS MRTX

2
MRTX / Mirati Therapeutics, Inc. null

2018-08-21 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,2]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
MRTX

2
MRTX / Mirati Therapeutics, Inc. 10-Q (Quarterly Report)

2018-08-20 sec.gov
Document Table of Contents UNITED STATES
MRTX

4
BeiGene Reports Second Quarter 2018 Financial Results

2018-08-09 globenewswire
CAMBRIDGE, Mass. and BEIJING, China, Aug. 09, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported recent business highlights and financial results for the second quarter and first half of 2018.
CICHY CELGZ MRTX CELG BGNE CICHF CCB 0939

2
MRTX / Mirati Therapeutics, Inc. FORM 8-K (Current Report)

2018-08-08 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 MRTX

11
Mirati Therapeutics: Innovating Stellar Molecules For Cancer Treatment

2018-08-07 seekingalpha
Mirati is a gift that keeps on giving, as the company logged astronomical profits for shareholders.
BRK.A CELGZ AZN MRTX CELG BGNE NVS LLY BMY

2
MRTX / Mirati Therapeutics, Inc. 10-Q (Quarterly Report)

2018-08-01 sec.gov
Document Table of Contents UNITED STATES
MRTX

2
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

2018-08-01 zacks
The Invesco DWA SmallCap Momentum ETF (DWAS - Free Report) was launched on 07/19/2012, and is a passively managed exchange traded fund designed to offer broad exposure to the Small Cap Blend segment of the US equity market.
PLUS AXGN MRTX

2
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

2018-07-09 zacks
Launched on 07/19/2012, the Invesco DWA SmallCap Momentum ETF (DWAS - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Blend segment of the US equity market.
AXGN MRTX MGPI CVRR

67
CNNX / CONE Midstream Partners LP - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-29 fintel.io
CONE Midstream Partners LP (NYSE:CNNX) has 4 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7,112,254 shares. Largest shareholders include Noble Energy Inc, MetLife Securities, Inc, Dreman Value Management, L L C, and Acorn Wealth Advisors, Llc. CONE Midstream Partners LP (NYSE:CNNX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.
NBL MRTX CNNX CNXM

MRTX: Mirati Therapeutics Analysis and Research Report

2018-06-26 - Asif

Overview Mirati Therapeutics, Inc. is a clinical-stage oncology company developing product candidates to address the genetic, epigenetic and immunological promoters of cancer. The company's precision oncology clinical programs utilize next-generation genomic testing to identify and select cancer patients who are most likely to benefit from targeted drug treatment. In immuno-oncology, Mirati Therapeutics is advancing clinical programs where the ability of its product candidates to improve the immune environment of tumor cells may enhance and expand the efficacy of existing cancer immunotherapy medicines when given in combination. The company's preclinical programs include potentially first-in-class and best-in-class product candidates specifically designed to address mutations and tumors where few treatment options exist. The company approach each of its discovery and development programs with a singular focus: to translate its deep understanding of the molecular drivers of canc...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to MRTX / Mirati Therapeutics, Inc. on message board site Silicon Investor.

MRTX Mirati Therapeutics MRTX Mirati Therapeutics MRTX Mirati Therapeutics
CUSIP: 60468T105